Intravenous thrombolysis in acute ischemic stroke after POLKARD: one center analysis of program impact on clinical practice

• Published in: Advances in medical sciences Vol. 56; no. 2; pp. 231 - 240
• Main Authors: Arkuszewski, M, Targosz-Gajniak, M, Swiat, M, Patalong-Ogiewa, M, Pieta, M, Opala, G
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Urban & Partner Sp. z o.o 01.12.2011; Elsevier Limited
• Subjects: Aged; Cardiology - methods; Female; Humans; Ischemia - pathology; ischemic stroke; Male; Middle Aged; mortality; outcome; Outcome Assessment (Health Care); Poland; proportion; Prospective Studies; Regression Analysis; Retrospective Studies; Risk Factors; Stroke - therapy; thrombolysis; Thrombolytic Therapy - methods; time delays; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome; Poland; thrombolysis; mortality; time delays; proportion; ischemic stroke; outcome
• ISSN: 1896-1126; 1898-4002
• DOI: 10.2478/v10039-011-0045-8

Intravenous thrombolysis in the acute ischemic stroke was initiated in Poland within the National Cardiovascular Disease Prevention and Treatment Program POLKARD in the years 2003–2008. Since 2009 the procedure has been reimbursed by the National Health Fund (Narodowy Fundusz Zdrowia – NFZ). The purpose of the presented study was to assess whether the change of financing institution was associated with the change in proportion of patients treated and with any of the clinical parameters or stroke outcomes. We reviewed the data of the 90 consecutive patients with acute ischemic stroke treated with intravenous thrombolysis within 3-hours from symptoms onset. The differences between the POLKARD period and the year 2009, regarding clinical parameters, time delays, death rates and functional outcomes on day 90 after the stroke were analyzed. The association of outcome measures with baseline characteristics of the patients was analyzed with binary logistic regression. In 2009 there was a significant increase in the proportion of patients treated (7.6%, 95%CI 5.3–10.7%, vs. 4.3%, 95%CI 3.3-5.5% respectively, p=0.013). There were no differences in age, baseline neurological presentation, prevalence of stoke risk factors, treatment time delays or hemorrhagic complications. Higher, but not significantly, 90-day mortality was observed (32.1%, 95%CI 13.3-54.1% vs. 16.1%, 95%CI 6.4–29.7% respectively, p=0.101). Baseline neurological deficits and in-hospital treatment time delays were significant predictors of disability and death. After the Polish Ministry of Health program POLKARD termination and elimination of the reimbursement limits, higher proportion of ischemic stroke patients could be treated with the intravenous thrombolysis.